Author/Authors :
Latif, ZA BIRDEM Hospital - Department of Endocrinology, Bangladesh , Pathan, MF BIRDEM Hospital - Department of Endocrinology, Bangladesh , Mannan, MA Dhaka Medical College Hospital (DMCH) - Department of Endocrinology, Bangladesh , Siddiqui, MNI Mymensingh Medical College Hospital (MMCH) - Department of Endocrinology, Bangladesh , Ashrafuzzaman, SM BIRDEM Hospital - Department of Endocrinology, Bangladesh , Rahman, MM Novo Nordisk Pharma (Pvt.) Ltd. - Medical Services, Bangladesh , Sobhan, MJ Novo Nordisk Pharma (Pvt.) Ltd. - Medical Services, Bangladesh
Abstract :
The aim of A1chieve was to remedy the deficit of data on the efficacy and safety of insulin analoguesin routine clinical care in less well-resourced developed countries. To present results from the Bangladesh cohort of the A1chieve study receiving BIAsp 30 ± oral anti diabetic drugs. A1chieve was a 6-month, observational study of 66,726 people with type 2 diabetes, started on insulin detemir, insulin aspart or biphasic insulin aspart (BIAsp 30) in 28 countries across four continents. A total of 1,093 subjects were recruited from 49 sites in Bangladesh and 580 subjects initiated on BIAsp 30 were studied. In the entire cohort, treatment with BIAsp 30 for 24 weeks significantly reduced mean HbA1c (2.8%, p 0.001), fasting plasma glucose (4.0mmol/L, p 0.001) and post prandial plasma glucose (6.6mmol/L, p 0.001) levels from baseline. The rate of overall hypoglycaemic events in the entire cohort also reduced significantly at 24 weeks (1.86 to 0.02 events/person year, p 0.0001). BIAsp 30 can be considered as a safe and effective option for initiating as well as intensifying insulin therapy for type 2 diabetes.
